Evaluation der therapierefraktären Hypertonie vor invasiven Therapien

Schlüsselwörter

therapierefraktäre Hypertonie - Sympathikusablation - Compliance

Keywords

resistant hypertension - sympathetic denervation - compliance

• Literatur

• 1 Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681
• 2 Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients. Hypertension 2012; 60: 1485-1490
• 3 Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
• 4 Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642
• 5 Eide IK, Toriesen PA, Drolsum A et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2228
• 6 Jin Y, Kuznetsova T, Maillard M et al. Independent relations of left ventricular structure with the 24h-hour urinary excretion of sodium and aldosterone. Hypertension 2009; 54: 489-495
• 7 Jung O, Gechter JL, Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774
• 8 Kearny PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223
• 9 Krum H, Schlaich M, Whithbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281
• 10 Mahfoud F, Vonend O, Bruck H et al. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie. Dtsch Med Wochenschr 2011; 136: 2418-2424
• 11 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guideline for the management of arterial hypertension. The task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
• 12 Meisinger C, Heier M, Völzke H et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24: 293-299
• 13 Neuhauser H, Thamm M, Ellert U. Blood pressure in Germany 2008-2011: results of the German Health Interview and Examination Survey for Adults (DEGS 1). Bundesgesundheitsbl 2013; 56: 795-801
• 14 Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125: 1594-1596
• 15 Shimbo D, Levitan EB, Booth JN et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens 2013; 31: 370-376
• 16 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
• 17 Verloop WL, Vink EE, Voskuil M et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens 2013; 31: 1662-1668